Fibroblast growth factor receptor 2 IIIc as a therapeutic target for colorectal cancer cells

Molecular Cancer Therapeutics

Volumn 11, Issue 9, 2012, Pages 2010-2020

  Matsuda, Yoko ^a   Hagio, Masahito ^a   Seya, Tomoko ^a   Ishiwata, Toshiyuki ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2 IIIC; FIBROBLAST GROWTH FACTOR RECEPTOR 2 IIIC ANTIBODY; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGAR MEDIUM; AGED; ANCHORAGE DEPENDENT GROWTH; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CARCINOMA CELL; CECUM; CELL ADHESION; CELL DEATH; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; COLORECTAL POLYP; CONTROLLED STUDY; DISTANT METASTASIS; DNA MICROARRAY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EPITHELIUM HYPERPLASIA; EXTRACELLULAR MATRIX; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTESTINE EPITHELIUM CELL; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SUBCUTANEOUS TISSUE; TUMOR VOLUME; WESTERN BLOTTING;

ADENOCARCINOMA; ADENOMA; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ISOFORMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; TRANSCRIPTOME;

EID: 84866095723     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0243     Document Type: Article

References (33)

1. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 2009;100:1704-19.
2. Cho KR, Vogelstein B. Genetic alterations in the adenoma-carcinoma sequence. Cancer 1992;70:1727-31.
3. Tahara E. Growth factors and oncogenes in human gastrointestinal carcinomas. J Cancer Res Clin Oncol 1990;116:121-31. (Pubitemid 20271913)
4. Ochs AM, Wong L, Kakani V, Neerukonda S, Gorske J, Rao A, et al. Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer 2004;4:262-7. (Pubitemid 40012323)
5. Narita K, Fujii T, Ishiwata T, Yamamoto T, Kawamoto Y, Kawahara K, et al. Keratinocyte growth factor induces vascular endothelial growth factor-A expression in colorectal cancer cells. Int J Oncol 2009;34:355-60.
6. Sato T, Oshima T, Yoshihara K, Yamamoto N, Yamada R, Nagano Y, et al. Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer. Oncol Rep 2009;21:211-6.
7. Yoshino M, Ishiwata T, Watanabe M, Komine O, Shibuya T, Tokunaga A, et al. Keratinocyte growth factor receptor expression in normal colorectal epithelial cells and differentiated type of colorectal cancer. Oncol Rep 2005;13:247-52.
8. Itoh N. The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease. Biol Pharm Bull 2007;30:1819-25. (Pubitemid 47607758)
9. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004;20:563-9. (Pubitemid 39314564)
10. Katoh M. FGF signaling network in the gastrointestinal tract (review). Int J Oncol 2006;29:163-8.
11. Ibrahimi OA, Eliseenkova AV, Plotnikov AN, Yu K, Ornitz DM, Mohammadi M. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proc Natl Acad Sci U S A 2001; 98:7182-7. (Pubitemid 32567923)
12. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005;16:107-37. (Pubitemid 40616111)
13. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139-49. (Pubitemid 40616112)
14. Matsuda Y, Ishiwata T, Yamahatsu K, Kawahara K, Hagio M, Peng WX, et al. Overexpressed fibroblast growth factor receptor 2 in the invasive front of colorectal cancer: a potential therapeutic target in colorectal cancer. Cancer Lett 2011;309:209-19.
15. Kudo M, Ishiwata T, Nakazawa N, Kawahara K, Fujii T, Teduka K, et al. Keratinocyte growth factor-transfection-stimulated adhesion of colorectal cancer cells to extracellular matrices. Exp Mol Pathol 2007;83:443-52. (Pubitemid 350087022)
16. Kwabi-Addo B, Ropiquet F, Giri D, Ittmann M. Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate 2001;46:163-72.
17. Valve E, Martikainen P, Seppanen J, Oksjoki S, Hinkka S, Anttila L, et al. Expression of fibroblast growth factor (FGF)-8 isoforms and FGF receptors in human ovarian tumors. Int J Cancer 2000;88: 718-25.
18. Drugan CS, Paterson IC, Prime SS. Fibroblast growth factor receptor expression reflects cellular differentiation in human oral squamous carcinoma cell lines. Carcinogenesis 1998;19:1153-6. (Pubitemid 28375414)
19. Cha JY, Lambert QT, Reuther GW, Der CJ. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res 2008;6:435-45. (Pubitemid 351416534)
20. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006;66:11271-8. (Pubitemid 46009956)
21. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 2009;75:196-207.
22. Baum B, Settleman J, Quinlan MP. Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 2008;19:294-308.
23. Ishiwata T, Matsuda Y, Yamamoto T, Uchida E, Korc M, Naito Z. Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am J Pathol 2012; 180:1928-41.
24. Hamilton SR, Bosman FT, Boffetta P, Ilyas M, Morreau H, editors. Tumours of the colon and rectum. 4th ed. Lyon, France: IARC Press; 2010.
25. Kawase R, Ishiwata T, Matsuda Y, Onda M, Kudo M, Takeshita T, et al. Expression of fibroblast growth factor receptor 2 IIIc in human uterine cervical intraepithelial neoplasia and cervical cancer. Int J Oncol 2010;36:331-40.
26. Matsuda Y, Naito Z, Kawahara K, Nakazawa N, Korc M, Ishiwata T. Nestin is a novel target for suppressing pancreatic cancer cell migration, invasion and metastasis. Cancer Biol Ther 2011;11:512-23.
27. Seiden-Long I, Navab R, Shih W, Li M, Chow J, Zhu CQ, et al. Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells. Carcinogenesis 2008;29:647-55. (Pubitemid 351404883)
28. Rothe C, Urlinger S, Lohning C, Prassler J, Stark Y, Jager U, et al. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune systemwith a novel display method for efficient selection of high-affinity antibodies. J Mol Biol 2008;376:1182-200.
29. LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics 2009;2:67.
30. =GSE38544.
31. Ogawa S, Ochi T, Shimada H, Inagaki K, Fujita I, Nii A, et al. Anti-PDGFB monoclonal antibody reduces liver fibrosis development. Hepatol Res 2010;40:1128-41.
32. Steidl S, Ratsch O, Brocks B, Durr M, Thomassen-Wolf E. In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification. Mol Immunol 2008;46:135-44.
33. Nagy ZA, Hubner B, Lohning C, Rauchenberger R, Reiffert S, Tho-massen-Wolf E, et al. Fully human, HLA-DR-speci fic monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med 2002;8:801-7.